BioCardia's CardiAMP HF Phase 3 trial accepted for late-breaking presentation at ACC 2025

BioCardia, Inc.

Results of double-blind, randomized, placebo-controlled CardiAMP HF Phase 3 study accepted for late-breaking symposium at ACC 2025 in Chicago, March 29-31.
Presentation by Dr. Amish N. Raval on March 30, 2025, in Featured Clinical Research II session.
CardiAMP HF trial evaluates autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF).
Late-breaking clinical trial session highlights key upcoming results at a leading cardiovascular conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.